Spago Nanomedical has momentarily halted its clinical study SPAGOPIX-01 at Uppsala University Hospital due to the COVID-19 pandemic.
Uppsala University Hospital has issued internal recommendations for clinical studies as a consequence of the COVID-19 outbreak. Within different departments reprioritizing of resources is made due to this which means that SPAGOPIX-01 momentarily is paused.
Through its CRO the company is maintaining a close dialogue with the hospital in order to as quick as possible be able to resume the patient recruitment. The study is further initiated at the Sahlgrenska Hospital in Gothenburg and the company is also investigating the possibility to broaden the study with an additional center.
SpagoPix is a cancer selective MRI contrast agent with the potential to significantly improve cancer diagnostics. Through earlier, enhanced and more precise visualization of soft tissue tumors and metastases, the chances of successful treatment of cancer patients are improved.
Photo of Mats Hansen, CEO of Spago Nanomedical and SpagoPix. Photo: Emil Aaltonen